-
Science Saturday: Collaborative study discovers new disease behind patient’s recurring blood clots
Share this:
In 2018, a male patient in his 60s began experiencing chest pains, which turned out to be caused by multiple blood clots in his lungs. As he visited several institutions in and around his home state of Michigan, doctors conducted the typical testing panels to look for a condition called thrombophilia that causes blood clots to form too easily. But tests did not confirm the known thrombophilic conditions.
"So people were not able to give him an answer as to why he had thrombosis with potentially life-threatening clots," says Anand Padmanabhan, M.B.B.S., Ph.D., a Mayo Clinic laboratory medicine and pathology specialist.
A collaboration between Mayo Clinic and University of Michigan Health solved the medical mystery. The work led to the development at Mayo Clinic of a new methodology to test for clotting disease and the identification of a previously unknown blood clotting condition.
A clotting condition that didn't add up
In addition to the unexplained clotting, several details about the man's condition baffled the clinicians he had seen. Why, for instance, did he have intermittent low platelet counts, known as thrombocytopenia? He was seen by Jordan Schaefer, M.D., a hematologist at University of Michigan who specializes in thrombotic disorders.
Even though he had normal platelet values, the patient’s history was concerning for the medication-related complication known as heparin-induced thrombocytopenia, or HIT. Testing confirmed this diagnosis. However, the most mysterious detail of his condition was that even though the man was no longer taking the blood-thinning drug heparin, he continued to test positive for HIT in follow-up.
Read the rest of the article on the Discovery's Edge blog.
____________________________________________
Other Mayo Clinic medical research websites:
- Research at Mayo Clinic
- Mayo Clinic Laboratories
- Center for Individualized Medicine
- Center for Regenerative Biotherapeutics
- Center for the Science of Health Care Delivery
- Mayo Clinic Comprehensive Cancer Center
Share this:
Related articles
ROCHESTER, Minn. — Patients who received the anticoagulant drug warfarin after bioprosthetic aortic valve replacement had lower incidence of mortality and a decreased risk of ...
When Joanina Gicobi began her Ph.D. degree five years ago at Mayo Clinic Graduate School of Biomedical Sciences, she was interested in thinking creatively about ways ...
With age, cells can experience senescence, a state where they stop growing but continue releasing inflammatory and tissue-degrading molecules. When a person is young, the ...